Somatostatin and its analogues have diverse indications in the work—up and treatment of the cancer patient. These range from diagnosis and localization with octreotide scintigraphy to decreasing postoperative complications following pancreaticoduodenectomy for pancreatic cancer. In addition, somatostatin has direct inhibitory activity on the proliferation of some human cancer cells, and has been utilized as antineoplastic therapy.1 Despite its broad spectrum of activity in the cancer patient and its diverse inhibitory properties, the effect of somatostatin on cancer cachexia and protein metabolism in the cancer patient has not been defined. The purpose of this chapter is to provide a background on the properties and function of somatostatin in the cancer patient, and to discuss the effect somatostatin may have on metabolism in the tumor-bearing host. Experimental data from animal models will be presented which support the use of somatostatin anologues as a means for inhibiting hormonal secretion in the tumor-bearing host. This may have a significant impact on cancer cachexia.
KeywordsAdenoma Serotonin Enzymatic Degradation Histamine Half Life
Unable to display preview. Download preview PDF.
- 6.Patel YC, Greenwood MT, Warszynska A, Panetta R, Srikant CB. All five cloned human somatostatin receptors (hSSTR1–5) are functionally coupled to adenylyl cyclase. Biochem Biophys Res Commun 1994; 605–12.Google Scholar
- 15.Pederzoli P, Bassi C, Falconi M et al. Conservative treatment of external pancreatic fistulas with parenteral nutrition alone or in combination with somatostatin, glucagon, or calcitonin. Surg Gynecol Obstet 1986; 90: 1405–11.Google Scholar
- 16.Limburg B, Kommerfell B. Treatment of acute pancreatitis with somatostatin. N Engl J Med 1980; 303: 284–7.Google Scholar
- 18.Talley NJ, Turner I, Middleton WR. Somatostatin and symptomatic relief of irritable bowel syndrome. Lancet 1987; 2: 1114–7.Google Scholar
- 25.Canivet B, Le Cam A, Freychet P. Somatostatin: lack of effect of cyclic AMP release and amino acid transport in isolated rat hepatocytes. Diabetes Metab 1979; 5: 17–9.Google Scholar
- 30.Bartlett DL, Torosian MH. Biochemical and biological effects of somatostatin therapy on tumor growth and host metabolism. Int J Oncol. 1995; (in press).Google Scholar
- Bloom SR, Polak JM. Glucagonoma syndrome. [Review]. Am J Med 1987; 82:25–36.Google Scholar
- 42.Chance WT, vanLammeren FM, Chen MH, Murphy RF, Joffe SN, Fischer JE. Alteration in plasma levels of insulin and glucagon associated with cancer anorexia. Surg Forum 1983; 34: 441–3.Google Scholar
- 45.Bartlett DL, Charland SL, Torosian MH. Reversal of tumor-associated hyperglucagonemia as treatment for cancer cachexia. Surgery1995; 118(1):87–97.Google Scholar
- 51.Shaw JH, Wolfe RR. Metabolic intervention in surgical patients. An assessment of the effect of somatostatin, ranitidine, naloxone, diclophenac, dipyridamole, or salbutamol infusion on energy and protein kinetics in surgical patients using stable and radioisotopes. Ann Surg 1988; 207: 274–82.PubMedCrossRefGoogle Scholar
- 54.Torosian MH, Williams N, Nguyen H. Effect of nutrition on tumor growth and cell cycle kinetics. J Parent Ent Nutr 1989; 13 (7S): 33–8.Google Scholar